AbbVie Inc.
ABBVleaderAbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.
製品と売上
製品別売上シェア
売上内訳 ($56.3B)
静的データ（リアルタイム財務ロード中…）
セグメント構成と主要顧客
製品詳細
Next-generation immunology biologics replacing Humira revenue
Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)
Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting
サプライチェーン関係
マクロ・市場概況
GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집
GLP-1 시장 규모 (2030E)
mRNA 암백신 임상 성공률
AI 신약개발 단계
PFE/MRNA 52주 변화
次の主要イベント
機関投資家シグナル
| 機関 | アクション | 価値 | 四半期 | 申告日 |
|---|---|---|---|---|
| BlackRock | accumulating | $717M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $272M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $277M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $21M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $43M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $507M | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $571M | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $8.8B | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $6.6B | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $563M | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $923M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $346M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $608M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $6M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $1.9B | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $83M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $30M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $643M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $64M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $11M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $15M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $399K | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $460M | 2024.06 | 2024-08-13↑ |
| Vanguard Group | accumulating | $2.3B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $193M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $37.1B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $754M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $882M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $9M | 2025.12 | 2026-01-29↑ |
| State Street | accumulating | $18.5B | 2025.12 | 2026-02-13↑ |
| Wellington Management | accumulating | $3.1B | 2025.12 | 2026-02-17↑ |
| Wellington Management | accumulating | $65M | 2025.12 | 2026-02-17↑ |
| Wellington Management | reducing | $32M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $46M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $24M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $42M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $37M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $5M | 2025.12 | 2026-02-17↓ |
| Wellington Management | accumulating | $93M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $3.8B | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $280M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $822M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $41M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $218M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $25M | 2025.12 | 2026-02-17↑ |
最新ニュース
AI分析
AbbVie Inc.のAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。
企業情報
セクター概況 — 제약 / 바이오
セクターニュースGLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집
GLP-1 시장 규모 (2030E)
mRNA 암백신 임상 성공률
AI 신약개발 단계
PFE/MRNA 52주 변화
主要テーマ
- •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
- •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
- •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성
次の主要イベント
- ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
- ◆MRNA 암백신 FDA BLA 제출 예정